Evolved Aztreonam Resistance Is Multifactorial and Can Produce Hypervirulence in <italic toggle="yes">Pseudomonas aeruginosa</italic>
ABSTRACT While much attention has been focused on acquired antibiotic resistance genes, chromosomal mutations may be most important in chronic infections where isolated, persistently infecting lineages experience repeated antibiotic exposure. Here, we used experimental evolution and whole-genome seq...
Guardado en:
Autores principales: | Peter Jorth, Kathryn McLean, Anina Ratjen, Patrick R. Secor, Gilbert E. Bautista, Sumedha Ravishankar, Amir Rezayat, Jayanthi Garudathri, Joe J. Harrison, Rachel A. Harwood, Kelsi Penewit, Adam Waalkes, Pradeep K. Singh, Stephen J. Salipante |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
American Society for Microbiology
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/3789d0f4355743ab928140bb13ba807a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Tigeciclina versus vancomycin más aztreonam en el tratamiento de infecciones complicadas de piel y tejidos blandos: Experiencia en Latinoamérica
por: Campos B,M. Isabel, et al.
Publicado: (2009) -
Polymyxin Combinations Combat <italic toggle="yes">Escherichia coli</italic> Harboring <italic toggle="yes">mcr-1</italic> and <italic toggle="yes">bla</italic><sub>NDM-5</sub>: Preparation for a Postantibiotic Era
por: Zackery P. Bulman, et al.
Publicado: (2017) -
Struggle To Survive: the Choir of Target Alteration, Hydrolyzing Enzyme, and Plasmid Expression as a Novel Aztreonam-Avibactam Resistance Mechanism
por: Ke Ma, et al.
Publicado: (2020) -
Antimicrobial Activity of Aztreonam in Combination with Old and New β-Lactamase Inhibitors against MBL and ESBL Co-Producing Gram-Negative Clinical Isolates: Possible Options for the Treatment of Complicated Infections
por: Gianluca Morroni, et al.
Publicado: (2021) -
Efficient and Scalable Precision Genome Editing in <italic toggle="yes">Staphylococcus aureus</italic> through Conditional Recombineering and CRISPR/Cas9-Mediated Counterselection
por: Kelsi Penewit, et al.
Publicado: (2018)